Health Equity Drives Small Molecule Strategy At Serna Bio

Serna Bio is using machine learning and RNA biology to create a platform for the discovery of small molecule modulators of RNA. The startup will seek fresh funding in 2024 and is on the hunt for creative biopharma partnerships.

small molecule
• Source: Shutterstock

Serna Bio founder and CEO Rabia Khan told In Vivo that today the biopharma industry “does not have the toolkit to find small molecules to target RNA, but small molecules are the modality that most pharma companies understand.”

Serna, formally known as Ladder Therapeutics, aims to use “advanced computational methods like machine learning to improve our understanding of...

More from C-Suite Speaks

More from Leadership